Treatment with the type iv phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1197-1204

  Carcillo, Joseph A ^a   Herzer, William A ^a   Mi, Zaichuan ^a   Thomas, Neal J ^a   Jackson, Edwin K ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ANIMALS; BLOOD PRESSURE; CYCLIC AMP; ENDOTOXEMIA; HEART RATE; HUMANS; KIDNEY; MALE; MESENTERY; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW;

EID: 0030441043     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. BEAVO, J. A., CONTI, M. AND HEASLIP, R. J.: Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46: 399-405, 1994.
2. BEAVO, J. A. AND REIFSNYDER, D. H.: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of specific inhibitors. Trends Pharmacol. Sci. 11: 150-155, 1990.
3. BEGANY, D. P., CARCILLO, J. A., HERZER, W. A., MI, Z. AND JACKSON, E. K.: Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J. Pharmacol. Exp. Ther. 278: 37-41, 1996.
4. CHINI, C. C., CHINI, E. N., WILLIAMS, J. M., MATOUSOVIC, K. AND DOUSA, T. P.: Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int. 46: 28-36, 1994.
5. CHIU, N., PARK, I. AND REID, I. A.: Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram. J. Pharmacol. Exp. Ther. 276: 1073-1077, 1996.
6. CHURCHILL, P. C., BIDANI, A. K. AND SCHWARTZ, M. M.: Renal effects of endotoxin in the male rat. Am. J. Physiol. 253: F244-F250, 1987.
7. CONGER, J. D., FALK, S. A. AND GUGGENHEIM, S. J.: Glomerular dynamics and morphologic changes in the generalized Schwartzman reaction in postpartum rats. J. Clin. Invest. 67: 1334-1346, 1981.
8. DENT, G., GIEMBYCZ, M. A., EVANS, P. M., RABE, K. F. AND BARNES, P. J.: Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibition of the type IV phosphodiesterase: Interaction with beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther. 271: 1167-1174, 1994.
9. FISCHER, W., SCHUDT, C. AND WENDEL, A.: Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem. Pharmacol. 45: 2399-2404, 1993.
10. KAMBAYASHI, T., JACOB, C. O., ZHOU, D., MAZUREK, N., FONG, M. AND STRASSMAN, G.: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155: 4909-4916, 1995.
11. KIKERI, D., PENNELL, J. P., HWANG, K. H., JACOB, A. I., RICHMAN, A. V. AND BOURGOIGNIE, J. J.: Endotoxemic acute renal failure in awake rats. Am. J. Physiol. 250: F1098-F1106, 1986.
12. LANDOW, L. AND ANDERSEN, L. W.: Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol. Scand. 38: 626-639, 1994.
13. LIU, P., MCGUIRE, G. M., FISHER, M. A., FARHOOD, A., SMITH, C. W. AND JAESCHKE, H.: Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock 3: 56-62, 1995.
14. MORRISON, D. C. AND RYAN, J. L.: Endotoxins and disease mechanisms. Annu. Rev. Med. 38: 417-432, 1987.
15. PRABHAKAR, U., LIPSHUTZ, D., BARTUS, J. O., SLIVJAK, M. J., SMITH, E. F., III, LEE, J. C. AND ESSER, K. M.: Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16: 805-816, 1994.
16. SEKUT, L., BRACKEEN, M. F., YARNALL, D., STIMPSON, S. A., NOEL, L. S., BATEMANFITE, R., CLARK, R. L., MENIUS, J. A., JR. AND CONNOLLY, K. M.: Antiinflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. 100: 126-132, 1995.
17. SEMMLER, J., WACHTEL, H. AND ENDRES, S.: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15: 409-413, 1993.
18. TURKEY, J. H., MARSHALL, D. H., BROWNJOHN, A. M., ELLIS, C. M. AND PARSONS, F. M.: The evolution of acute renal failure, 1956-1988. Q. J. Med. 74: 83-104, 1990.
19. VERGHESE, M., W. MCCONNELL, R. T., STRICKLAND, A. B., GOODING, R. C., STIMPSON, S. A., YARNALL, D. P., TAYLOR, J. D. AND FURDON, P. J.: Differential regulation of human monocyte-derived TNFα and IL-1β by the type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272: 1313-1320, 1995.